


The fund’s investment objective is to achieve capital growth. The fund will invest in healthcare, medical services and related products and companies on a world wide basis. Investment will be in directly held transferable securities. The fund may also invest in collective investment schemes, warrants and money market instruments.
| Name | % Net Assets |
|---|---|
| Roche Holding | 6.6% |
| Johnson & Johnson | 5.5% |
| Novartis | 5.4% |
| Bristol Myers Squibb | 4.0% |
| Amgen | 3.9% |
| Gilead Sciences | 3.6% |
| UnitedHealth Group | 3.2% |
| Pfizer | 3.1% |
| Merck | 2.8% |
| Bayer | 2.7% |
| Key | % Net Assets |
|---|---|
| 6.6% | |
| 5.5% | |
| 5.4% | |
| 4.0% | |
| 78.5% |
| Date | 20-Aug-2025 |
|---|---|
| NAV | 244.00p |
| Currency | GBP |
| Change | 0.20p |
| % | 0.08% |
| YTD change | -20.10p |
| YTD % | -7.61% |
| Fund Inception | 22/05/2000 |
|---|---|
| Fund Manager | n/a |
| TER | 0.87 (15-Feb-2012) |
| Minimum Investment | |
|---|---|
| Initial | n/a |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | n/a |
| Annual Mang't | 0.75% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research